Treatment of Helicobacter pylori infection

Current Opinion in Gastroenterology

Volumn 16, Issue 1, 2000, Pages 32-39

  Vakil, Nimish ^a   Go, Mae F ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; RANITIDINE;

ACID SECRETION; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFICACY; DYSPEPSIA; ERADICATION THERAPY; FECES ANALYSIS; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PATHOGENESIS; PEPTIC ULCER; PRACTICE GUIDELINE;

EID: 0034053640     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200001000-00006     Document Type: Article

References (45)

1. 1 Rigas B, Feretis C, Papavassiliou ED: J Lykoudis: an unappreciated discoverer of the infectious etiology and treatment of peptic ulcer disease. Lancet 1999, In press. This paper discusses an early proponent of an infectious cause for peptic ulcer disease and his unsuccessful efforts to obtain support for his belief.
2. 2 Vaira D, Malfertheiner P, Megraud F, Axon ATR, Delentre M, Hirschl A, et al.: Diagnosis of Helicobacter pylori infection with a new non-invasive antigen based assay. Lancet 1999, 354:30-33. This large, controlled European trial demonstrates the efficacy of the stool antigen test.
3. 2 blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994, 343:811-815.
4. 4 American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 1998, 114:579-581.
5. 5 Lassen AT, Pederson FM, Bytzer P, de Muckadel Schaffalitzky OB: H. pylori test and treat or prompt endoscopy for dyspeptic patients in primary care. A randomized controlled trial of 2 management strategies: one year follow-up. Gastroenterology 1998, 114:A196.
6. 6 Heaney A, Collins JSA, Watson RGP, McFarland RJ, Bamford KB, Tham TCK: A prospective randomized trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia referred to a hospital clinic. Gut 1999, 45:186-190.
7. 7 Ladabaum U, Fendrick AM, Schieman JM: Utilization and outcomes of office-based testing for Helicobacter pylori (HP) in symptomatic primary care patients. Gastroenterology 1998, 114:A24.
8. 8 Blum AL, Talley NJ, O'Morain, Veldhyyzen van Zanten S, Labenz J, Stolte M, et al.: Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998, 339:1875-1881.
9. 9 Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E, on behalf of the Optimal Regimen Cures Helicobacter pylori Induced Dyspepsia (ORCHID) Study Group: Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. BMJ 1999, 318:833-837.
10. 10 Talley NJ, Vakil N, Ballard ED, Fennerty B: Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999, 341:1106-1111.
11. 11 McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al.: Symptomatic benefit from eradicating H. pylori in patients with nonulcer dyspepsia. N Engl J Med 1998, 339:1869-1874. The above four papers are the major studies exploring the relationship between H. pylori eradication and symptoms in nonulcer dyspepsia.
12. 12 Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, et al.: Is acid suppression efficacious in non-ulcer dyspepsia? A double-blind randomized controlled trial with omeprazole. Gastroenterology 1998, 114:A305.
13. 13 Connor H: Helicobacter pylori and gastro-esophageal reflux disease-clinical implications and management. Aliment Pharmacol Ther 1999, 13:117-127.
14. 14 Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G: Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997, 112:1442-1447.
15. 15 Vakil N, Hahn B, McSorley D: Recurrent symptoms and gastro-esophageal reflux disease in patients with duodenal ulcer after treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2000, In press. The data presented in this paper, on the emergence of heartburn and reflux esophagitis in patients with ulcer after H. pylori eradication therapy, conflict with those of Labenz et al. [14].
16. 16 Gisbert J, De-Pedro C, Barreiro A, Cabrera M, Valle J, Cruzado A, Pajares J: H. pylori and gastro-esophageal reflux disease: lack of influence of infection on pH-metric and endoscopic findings. Gastroenterology 1999, 116:A172.
17. 17 Holtmann G, Cain C, Malfertheiner P: Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999, 117:11-16.
18. 18 Schenk B, Kuipers E, Klinkenberg-Knol E, Eskes S, Meuwissen S: Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999, 94:884-887.
19. 19 Vicari J, Peek R, Falk G, Goldblum J, Easley K, Schnell J, et al.: The sero-prevalence of cagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998, 115:50-57.
20. 20 Chan F, Sung J, Chung S, To K, Yung M, Leung C, et al.: Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997, 350:975-979
21. 21 Yeomans M, Tulassy Z, Juhasz L, Racz I, Howard J, van Rensberg J, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998, 338:719-726
22. 22 Taha A, Dahill S, Morran C, Hudson N, Hawkey C, Lee F, et al.: Neutrophils, H. pylori and NSAID ulcers. Gastroenterology 1999, 116:254-258.
23. 23 Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K: Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999, 116:1305-1309.
24. 24 Konturek J, Dembinski A, Konturek S, Stachura J, Domschke W: Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998, 114:245-255.
25. 25 Howden CW, Hunt RH: Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998, 93:2330-2338.
26. 26 Houben MHMG, van de Beek D, van 't Hoff BWM, van der Hulst RWM, Rauws EAJ, van der Ende A, et al.: PPI-triple therapy failure in Helicobacter pylori (Hp) infection: re-treatment with PPI-triple therapy or quadruple therapy? Digestion 1998, 59(suppl 3):413.
27. 27 Vd Wouden EJ, Thijs JC, can Zwet AA, et al.: Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate (RBC), clarithromycin (CLA), and metronidazole (MET) for H. pylori (Hp) infection. Gastroenterology 1998, 114:A323.
28. 28 Vakil N, Hahn B, McSorley D: Clarithromycin resistant Helicobacter pylori in the United States. Am J Gastroenterol 1998, 93:1432-1435.
29. 29 Nawaz A, Mohammed I, Ahsan K, Karakurum A, Hadjiyane C, Pellecchia C: Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Am J Gastroenterol 1998, 93:1175-1176.
30. 30 Jenks PJ, Labigne A, Ferrero RL: Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice. Antimicrob Agents Chemother 1999, 43:777-781.
31. 31 Kusters JG, Schuijffel DF, Gerrits MM, Zwet van AA, Vandenbroucke-Grauls MJE: A PBP-1A homologue is involved in stable amoxicillin resistance of Helicobacter pylori. Gastroenterology 1999, 116:A226.
32. 32 Krishnamurthy P, Parlow MH, Schneider J, Burroughs S, Wickland C, Vakil NB, et al.: Identification of a novel penicillin-binding protein from Helicobacter pylori. J Bacteriol 1999, 181:5107-5110.
33. 33 Sherman P, Hassall E, Hunt RH, Fallone CA, Veldhuyzen van Zanten S, Thomson ABR, and the Canadian Helicobacter Study Group: Canadian Helicobacter Study Group consensus conference on the approach to Helicobacter pylori infection in children and adolescents. Can J Gastroenterol 1999, 13:1-7. This was one of the first pediatric conferences to establish practice guidelines on the management of H. pylori infection on the basis of published evidence.
34. 34 Rowland M, Imrie C, Bourke B, Drumm B: How should Helicobacter pylori infected children be managed? Gut 1999, 45(suppl 1):136-139. This paper discusses the practical management of H. pylori infection in pediatric patients and examines literature on the association of H. pylori infection with systemic disorders.
35. 35 Rocha de Oliveira AM, Rocha GA, Queiroz DmdeM, Mendes EN, de Carvalho AST, Ferrari TCA, Nogueira AMMF: Evaluation of enzyme-linked immunosorbent assay for the diagnosis of Helicobacter pylori infection from different age groups with and without duodenal ulcer. J Pediatr Gastroenterol Nutr 1999, 28:157-161. These authors describe the accuracy of serologic assays for detection of H. pylori infection in pediatric patients related to patient age. Serologic assays may have significantly less sensitivity in very young pediatric patients.
36. 36 Camorlinga-Ponce M, Torres J, Perez-Perez G, Leal-Herrera Y, Gonzalez-Ortiz B, Madrazo de la Garza A, et al.: Validation of a serologic test for the diagnosis of Helicobacter pylori infection and the immune response to urease and CagA in children. Am J Gastroenterol 1998, 93:1264-1270.
37. 37 Mitchell HM, Hazell SL, Bohane TD, Hu P, Chen M, Li YY: The prevalence of antibody to CagA in children is not a marker for specific disease. J Pediatr Gastroenterol Nutr 1999, 28:71-75. This paper examines CagA antibody prevalence in various pediatric populations. The antibody is common in pediatric and adult Asian populations, independent of clinical presentation.
38. 13carbon urea breath test for the noninvasive detection of Helicobacter pylori in children: comparison with culture and determination of minimum analysis requirements. J Pediatr Gastroenterol Nutr 1999, 26:291-296.
39. 13C]-urea breath test in diagnosing Helicobacter pylori gastritis in pediatric patients. J Pediatr Gastroenterol Nutr 1999, 28:59-62.
40. 13C-urea breath test. J Pediatr Gastroenterol Nutr 1999, 27:275-280.
41. 41 Moshkowitz M, Reif S, Brill S, et al.: One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. Pediatrics 1998, 102:e14.
42. 42 Casswall TH, Alfven G, Drapinski M, Bergstrom M, Dahlstrom KA: One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 1998, 27:415-418.
43. 43 Raymond J, Kalach N, Bergeret M, Benhamou PH, Barbet JP, Gendrel D, Dupont C: Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in children. Antimicrob Agents Chemother 1998, 42:1334-1335.
44. 44 Kato S, Abukawa D, Furuyama N, Iinuma K: Helicobacter pylori reinfection rates in children after eradication therapy. J Pediatr Gastroenterol Nutr 1998, 27:543-546.
45. 45 Huang F-C, Chang M-H, Hsu H-Y, Lee P-I, Shun C-T: Long-term follow-up of duodenal ulcer in children before and after eradication of Helicobacter pylori. J Pediatr Gastroenterol Nutr 1999, 28:76-80.